Sh Ou - Irvine Medical Center, University of California

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 75 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)

F. Cappuzzo,V. Moreno Garcia,S-H. I. Ou,M. Brandao, M. F. Sanmamed, C. Helissey, M. Wislez, J. A. Call, S. Grisanti, M. L. Johnson, V. Boni, P. Jamme,

Annals of Oncology (2023): S1671-S1671

引用0浏览0引用

Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC

Z. L. Arter, M. Nagasaka,S-H. I. Ou

ANNALS OF ONCOLOGY (2023): S1687-S1688

引用0浏览0引用

8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency

P.A. Jänne, A. Spira,G.J. Riely, S. Gadgeel, R. Heist,S-H.I. Ou,M.L. Johnson,J. Sabari, K. Velastegui, J.G. Christensen, W. Yang, K. Anderes,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S41-S42

引用0浏览0引用

LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers

N. Triphuridet, M. Nagasaka, E. Shum,S-H. I. Ou

ANNALS OF ONCOLOGY (2023): S1651-S1651

引用0浏览0引用

14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC)

W. Li, N. Yang,K. Li, H. Fan, Q. Yu, H. Wu, Y. Wang,X. Meng, J. Wu, Z. Wang,Y. Liu,X. Wang,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S47-S48

引用3浏览0引用

81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study

M.L. Johnson,S-H.I. Ou, E. Felip, C. Baik,B. Besse,J. Mazieres, D.R. Camidge, S. Gadgeel,A. Drilon, Y.Y. Elamin, G. Liu, J.E. Reuss,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S86-S87

引用0浏览0引用

A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC

S. M. Lim,B. C. Cho,J-Y. Han,S-W. Kim, K. H. Lee, M. Nagasaka, T. R. Baisamut, A. Jo, E. Seah, C. Kim,S-H. I. Ou

Annals of Oncology (2023): S1704-S1705

引用0浏览0引用

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

S.H. Ou,V. Moreno Garcia, I. Gil Bazo,H. Prenen, I. Moreno, M. Johnson,E. Castañón Álvarez, M. Nagasaka, S. Adeyemi, B. Barasa, K. Bol, P. Doze,

European Journal of Cancer（2022）

引用0浏览0引用

359P Epidermal growth factor receptor (EGFR) mutation testing and immunotherapy (IO) use associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US

S-H.I. Ou,M. Lin, Y. Yin, E. Curran, E. Churchill,Z. Piotrowska

Annals of Oncology (2022): S1581-S1581

引用0浏览0引用

77TiP TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors

M. Nagasaka,S. Sugawara,C-M. Choi, T. Okamoto, N. Yanagitani, K. Nosaki,T. Takahashi, Y. Fujiwara,H. Hayashi,J. Khoury,J. Nieva,A.E. Gabayan,

Annals of Oncology（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn